IHL.AX falls 10.87% to A$0.041 on ASX after hours 24 Mar 2026: volume 61.36M shows active trading

IHL.AX stock fell 10.87% to A$0.041 in after-hours trading on the ASX on 24 Mar 2026. Heavy liquidity drove the move, with 61,360,016 shares traded versus an average volume of 6,427,691. Traders flagged the drop after a weak intraday high of A$0.051 and a day low at A$0.041. Incannex Healthcare Limited (IHL.AX) remains a small-cap healthcare developer, market cap A$14,255,927.00, with an active clinical pipeline. Meyka AI provides this data-driven analysis and short-term outlook for most-active traders.

IHL.AX stock price action and liquidity

IHL.AX stock opened at A$0.047 and closed lower at A$0.041 in after hours on 24 Mar 2026. The intraday swing was A$0.051 high to A$0.041 low, a high relative range for this microcap. Volume spiked to 61,360,016, a relative volume of 9.55, which signals significant trader interest and short-term volatility.

Fundamentals, valuation and key ratios for IHL.AX stock

Incannex Healthcare (IHL.AX) reports EPS -1.30 and a negative PE. Market metrics show priceAvg50 A$0.0649 and priceAvg200 A$0.10285, underlining recent downtrend pressure. Book value per share is A$0.05474 and cash per share is A$0.02171. Price-to-book sits at 0.75, and price-to-sales is 14.06, reflecting thin revenue against equity. Current ratio is 9.02, indicating short-term liquidity well above peers.

Clinical pipeline and catalysts affecting IHL.AX stock

Incannex develops cannabinoid and psychedelic therapies including IHL-42X and Psi-GAD in Phase II trials. Completed Phase IIa programmes and multiple pre-clinical assets create milestone-driven upside. Clinical readouts, regulatory news, or licensing deals remain the primary catalysts that can swing price quickly for IHL.AX stock.

Technical outlook and trading interest in IHL.AX stock

Short-term technicals favour sellers; the stock trades below its 50-day average A$0.0649 and 200-day average A$0.10285. High volume and a -10.87% move indicate forced selling or position rotation. For short-term traders, watch the A$0.041 support and a relief resistance near A$0.065. Risk is high given low price and wide spreads.

Meyka AI grade and model forecast for IHL.AX stock

Meyka AI rates IHL.AX with a score out of 100. Meyka AI rates IHL.AX with a score of 64.83 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects solid cash ratios and a deep clinical pipeline, offset by negative earnings and volatile trading. These grades are informational only and not financial advice.

Meyka AI’s forecast model projects a 12-month base target of A$0.08. Versus the current price of A$0.041, that implies an upside of 95.12%. Forecasts are model-based projections and not guarantees.

Risks and sector context for IHL.AX stock

As a healthcare microcap on the ASX, IHL.AX stock faces clinical, regulatory, funding, and liquidity risks. The Healthcare sector on the ASX has lagged year-to-date, with average sector performance down 13.08%. Incannex’s high R&D spend at 9.24x revenue magnifies binary outcomes tied to trial results. Low market cap A$14,255,927.00 increases vulnerability to large order impact.

Final Thoughts

IHL.AX stock opened at A$0.047 and closed after hours at A$0.041 on 24 Mar 2026, down 10.87% on heavy volume of 61,360,016 shares. The immediate outlook is driven by liquidity and clinical-news risk rather than earnings strength. Fundamentals show negative EPS -1.30 and strong short-term liquidity, with a price-to-book of 0.75. For traders, key levels are A$0.041 support and A$0.065 resistance near the 50-day average. Long-term upside hinges on trial readouts and licensing deals. Meyka AI’s forecast model projects a 12-month base target of A$0.08, implying 95.12% upside from A$0.041, but this is a model projection, not a guarantee. Given the binary clinical risk and microcap volatility, our view supports a cautious HOLD for most investors, while active traders may exploit the high volume and sharp intraday moves. For the latest company updates, consult the Incannex site or trading screens and view real-time metrics on Meyka AI’s platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.